Human Insulin Market – Highlights
Market Research Future (MRFR) expects the human insulin market to attain a 4.72% CAGR between 2022 and 2030. The market size could touch USD 2.55 Billion by 2030. Change in lifestyle and high prevalence of obesity is the root cause of widespread occurrence of diabetes which induces demand for human insulin.
The rise in the global geriatric population who are at more risk of suffering from diabetes coupled with raising awareness of diabetes boosts the growth of the global human insulin market. Growing emphasis on diabetes management and technological advancement of insulin delivery devices such as the introduction of insulin pens have added fuel to ten growths of the market. The rise in several clinical trials for the development of novel therapies and treatment for diabetes purveyed by investment from pharmaceuticals companies has been a plus for the market growth.
However, the soaring price of human insulin, manufacturing complexities and complicated regulatory process for the approval of new drugs impede the growth of the market. Additionally, loss of patent acts as a major deterrent to the market growth. Development of biosimilars is a significant trend which is expected to increase the competition in the market and in turn, boost the market growth.
The global human insulin market report spans across the regions of the Americas, Europe, Asia Pacific, and the Middle East & Africa. North America accounts for the largest share of the global human insulin market owing to high health care spending, the presence of major players in the region who invest more money in R&D activities and inclination towards quality healthcare. The US is the largest market in the region followed by Canada while South America is expected to be the fastest growing region. The Europe market for human insulin is strong and is driven by the presence of a large pool of patients and the availability of funds for research and development in countries such as Germany. Asia Pacific market growth is supported by the presence of a vast patient base and rising prevalence of diabetes in the region. Improvement in healthcare infrastructure in countries such as China, India, and Japan are key to the growth of the market. Moreover, Asia Pacific hosts a huge geriatric population who are at more risk of acquiring diabetes. The Middle East & Africa market is expected to exhibit steady growth over the forecast period. Countries such as United Arab Emirates (U.A.E.), Saudi Arabia, and Oman have a robust healthcare infrastructure which drives the market in the Middle East while in Africa, weak economic conditions and under-developed healthcare sector deters the growth of the market.
The notable players operating in the global human insulin market include Biocon Ltd, ADOCIA, Julphar, Bristol-Myers Squibb Company, Oramed Pharmaceuticals, Inc, Sanofi, Tonghua Dongbao Pharmaceuticals Co., Ltd., Merck & Co, Pfizer, Inc, GlaxoSmithKline, and Novo Nordisk A/S.
The global human insulin market has been segmented based on type, methods, indication, and end users.
By methods, the market has been segmented into traditional human insulin and modern human insulin.
By indication, the market has been segmented into type 1 diabetes and type 2 diabetes. By end users, the market has been segmented into hospitals, forensic laboratories, research centres, and others.
In August 2018, Monarch Medical Technologies, a leading provider of electronic systems for inpatient glycemic management received US patent for its approach to inpatient insulin therapy. The approach has already been granted class II FDA clearance and underlines the uniqueness of the EndoTool technology.
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]